Editor's Letter

Published on 10 April 2025

Editor’s introduction to the initial issue of the 14th volume of GaBI Journal

In this first issue of 2025, we have some controversial criticism of an article previously published in GaBI Journal [1}, as well as a paper on pricing of biosimilars/biologicals after patent expiry and a meeting report on claimed weakening of FDA regulatory standards for biosimilars and its perceived effects on undermining physician confidence in biosimilar…

Author(s): Robin Thorpe, PhD, FRCPath

DOI: 10.5639/gabij.2025.1401.001

---

Editor's Letter

Published on 10 August 2025

A spectrum of generics and biosimilars: research, reports, and interviews

In this second issue of 2025, we have a diverse spectrum of publications which include one original research paper in the generics area and biosimilar-focused articles which comprise one special report, one meeting report, one interview and one sponsored article.  The first article in this issue is an Original Research paper titled ‘Therapeutic equivalence of…

Author(s): Robin Thorpe, PhD, FRCPath

DOI: 10.5639/gabij.2025.1402.006

---

Table Contents

Published on 15 April 2024

2024/1 GaBI Journal Table of Contents

Editor’s Letter First 2024 GaBI Journal issue highlights Original Research Budget impact analysis of a rituximab intravenous biosimilar in patients with follicular lymphoma and large B-cell non-Hodgkin lymphoma in Chile Pharmacokinetic bioequivalence studies of a new Etoricoxib tablet formulation developed using proprietary MiST technology — risk assessment and mitigation using GastroPlus software Perspective Comparative efficacy…

---

Original Research

Published on 23 March 2026

Real-world evaluation of dosing and haemoglobin A1c (HbA1c) in patients converted from insulin glargine (Lantus®) to insulin glargine (Basaglar®) in Saudi Arabia 

Introduction/Study objective: About 28% of Saudi Arabia population above 15 years old are diagnosed with diabetes. Basal insulin glargine Lantus and its’ biosimilar Basaglar, are long-acting insulin that regulate blood glucose levels over 24 hours. Patients switch between basal insulins for various reasons including adverse events, availability and cost. Switching should be done with careful…

Author(s): Salwa Almomen, MD, MSc, Fares Alrubaish, PharmD, Radwan Hafiz, PharmD, Ali M Alhomaidan, PhD

biosimilars, HbA1c, interchangeability, long-acting insulin analogues, switching, treatment conversion

DOI: 10.5639/gabij.2026.1501.

---

Special Report

Published on 24 March 2026

Budget impact analysis of implementation of biosimilars in a private health insurance company of large size in Southern Brazil 

Study objectives: To evaluate the budget impact of implementing a physician-led biosimilar switching programme within a large private health insurance company in Southern Brazil. Methods: This retrospective observational study analysed real-world data from a private payer perspective over 24 months (November 2022–October 2024). Six biologicals were included: infliximab, adalimumab, etanercept, rituximab, trastuzumab, and bevacizumab. In year…

Author(s): Rafael Gama, MD, MBA, Associate Professor Valderilio Feijó Azevedo, MD, PhD, MSc, Paula Heberle, MBA, Sergio Mauricio Menoncin, MSc, Daniela Toigo, MBA, Fabiana Aguiar, PG, Josymar Nascimento Júnior, MD, Ana Carolina Maciel, PG, Ricardo Luiz Pereira Bueno, BA, MHA, PhD

DOI: 10.5639/gabij.2026.1501.

---